BPH Flashcards
In the initial evaluation of patients with bothersome LUTS possibly attributed to BPH, clinicians SHOULD obtain:
GUIDELINE STATEMENT 1
Medical history (sexual hx, meds, overall fitness and health)
Physical exam
IPSS/AUA SS (symptom burden)
UA (bacteria, rbc, wbc, glucose, protein)
Options:
PVR, uroflow, pressure flow studies
What first options for management of LUTS SHOULD patients be counselled?
GUIDELINE STATEMENT 2
behavioral/lifestyle modifications (limit fluids qHS, with travel, caffeine, ETOH, spicy foods, chocolate, avoid constipation, increase activity, weight loss, kegels, timed voiding, double voiding, PFME +/- biofeedback)
medical therapy if additional tx necessary
referral for surgical evaluation (if seen by PCP)
After initiating treatment, when SHOULD providers assess response and how should patients be evaluated?
GUIDELINE STATEMENT 3
4-12 weeks after
(alpha blockers, beta 3 agonists, PDE5I and AC, shorter acting → as early as 4 weeks, longer acting 5-ARIs 3-6 mo)
IPSS/AUA SS
Uroflow and PVR
Consider Global Subjective Assessment
Patients with bothersome LUTS/BPH who elect initial medical management and do not have symptom improvement and/or intolerable side effects SHOULD:
GUIDELINE STATEMENT 4
undergo further evaluation and change medical management or proceed to surgery
consider UDS to confirm BOO vs. DO
trial additional medication classes
Prior to intervention for LUTS/BPH what SHOULD clinicians consider assessment of:
GUIDELINE STATEMENT 5
prostate size and shape via TRUS or abdominal US, cysto, cross sectional imaging (MRI/CT) if studies available (w/in 12 mo preferred)
volume: ellipsoid volume (height x length x width x 0.523)
*DRE and PSA unreliable in estimating size
Prior to sx intervention for BPH, what office based test SHOULD be done if it has not been done prior?
GUIDELINE STATEMENT 6
PVR
“large” PVR > 300 is worth monitoring, may warrant UDS vs. surgery
*does not seem to be a strong predictor of AUR
GUIDELINE STATEMENT 7
Uroflow
*must void 150 cc, no valsalva, characterize voiding dysfunction
Prior to surgical intervention for BPH/LUTs, what can be CONSIDERED if diagnostic uncertainty exists?
GUIDELINE STATEMENT 8
Pressure flow studies (UDS)
contractility, Qmax, peak voiding pressures, BOO
When considering minimally invasive sx for LUTS/BPH, what SHOULD clinicians counsel patients is possible in regards to outcomes?
GUIDELINE STATEMENT
treatment failure and need for secondary treatments
objective failure (urinary retention, reduction of Qmax, increased PVR, infection)
subjective failure (worsening IPSS, increase in duration of f/up or tx)
When treating BPH medically which class of medications would you start with and name all the medications in that class? What is the choice of medication bae on?
GUIDELINE STATEMENT 10
alpha blockers for bothersome, moderate-severe LUTS/BPH
alfuzosin, doxazosin, silodosin, tamsulosin, terazosin
GUIDELINE STATEMENT 11
choice of alpha blocker should be based on age, comorbidities, and different adverse effects (EjD, BP)
Which alpha blockers have the highest risk of orthostatic hypotension?
terazosin and doxazosin
tamsulosin best for BP, followed by alfuzosin and silodosin
What are alpha blockers with lowest risk of EjD?
doxazosin or terazosin
alfuzosin
*due to paralysis of smooth muscles in wall of prostatic ducts → anejaculation
What other surgical procedures warrant caution or further consideration in regards to starting alpha blockers?
GUIDELINE STATEMENT 12
with planned cataract surgery there is risk of intraoperative floppy iris syndrome
should be discussed with optho or defer initiation
discontinue 4-7 days prior to cataract, but does not completely eliminate IFIS
When is 5-ARI monotherapy appropriate for treatment of LUTS/BPH? What is the mechanism of action? what types are utilize?
GUIDELINE STATEMENT 13
prostatic enlargement > 30 cc on imaging, a PSA > 1.5, or palpable enlargement on DRE
Finasteride 5 mg (isoenzyme II only)
Dutasteride 0.5 mg (isoenzyme I and II)
*act via inhibition of alpha reductase (testosterone → DHT) leading to less available DHT → reduction in overall androgenic growth stimulus → atrophy and shrinkage (15-25% in 6 mo)
Reduction in prevalence of prostate cancer (RRR 25%, but more high grade prostate cancer dx)
What is meant by combination therapy? Utilization of which medication as part of this regimen can reduce the risk of urinary retention and need for surgery?
MTOPS trial
GUIDELINE STATEMENT 14
5ARIs alone or in combo with alpha blockers are recommended as tx option to prevent progression of LUTS/PGH and/or reduce risk of urinary retention and need for future prostate surgery
GUIDELINE STATEMENT 18
5-ARI in combo with alpha blockers should be offered as treatment only when prostate volume > 30 cc, PSA > 1.5, or palpable enlargement on DRE
What should clinicians counsel as adverse effects of 5-ARIs?
GUIDELINE STATEMENT 15
sexual side effects, physical side effects, low risk of CaP
MTOPS→ decline in sexual and ejaculatory function, decreased libido
Gynecomastia, dementia, depression, DMII (2x risk), post finasteride syndrome
What other indication can 5 ARIs be utilized for?
GUIDELINE STATEMENT 16
reduce intraoperative bleeding in peri- or postoperative need for blood txf after TURP or surgical intervention for BPH
Besides alpha blockers or 5ARIs what is an additional daily therapy for BPH/LUTs?
GUIDELINE STATEMENT 17
5 mg tadalafil should be discussed as a treatment option irrespective of comorbid ED
*can offer similar results seen with tamsulosin but does not improve UDS parameters
When are anticholinergics/beta-3 agonists indicated in treatment of BPH/LUTS?
GUIDELINE STATEMENT 19
alone or in combo with alpha blockers, may be offered as option with moderate-severe predominant storage LUTS
*AUR low in selected patients
PVR obtained, precautions used (gastric emptying, GI motility issues, narrow angle glaucoma, dementia)
GUIDELINE STATEMENT 20
beta-3-agonists in combo with alpha blocker may use used as treatment option in patients with moderate-severe predominant storage LUTS
Which combination therapy should not be prescribed for treatment of LUTS/BPH?
GUIDELINE STATEMENT 21
5 mg tadalafil and alpha blockers, offers no advantages in symptom improvement over either agent alone
no advantage of tadalafil and finasteride either
What are important elements to consider for TOV and what should patients be conselled?
GUIDELINE STATEMENT 22
prescribe alpha blockers prior to voiding trial for AUR
GUIDELINE STATEMENT 23
newly treated for AUR with alpha blockers, complete at least 3 days of tx before TOV
GUIDELINE STATEMENT 24
patients who pass TOV for AUR from BPH are at higher risk of recurrent AUR
What are indications to proceed to surgery for BPH?
GUIDELINE STATEMENT 25
renal insufficiency secondary to BPH
refractory urinary retention due to BPH
recurrent UTIs
recurrent bladder stones or gross hematuria due to BPH
with LUTS/BPH refractory or unwilling to use other therapies
How do you manage a bladder diverticulum in the presence of BPH?
GUIDELINE STATEMENT 26
should not perform surgery solely based on presence of asx bladder diverticulum; however, evaluation for BOO should be considered
(indications for surgery are same for BPH in general, treat BOO as indicated)
Surgical treatment options for BPH
List sx treatment options for BPH and recommenations:
GUIDELINE STATEMENT 27/28
TURP, monopolar or bipolar depending on expertise
GUIDELINE STATEMENT 29
open, lap, robotic assisted prostatectomy for large to very large prostates
GUIDELINE STATEMENT 30
TUIP, prostates < 30 cc, lower rate of RE or blood txf
GUIDELINE STATEMENT 31
Bipolar TUVP (rollerball, vaportrode, loop, button) → improved blood loss
GUIDELINE STATEMENT 32
PVP should be offered using 120 W or 180 W platforms (anticoagulation)
GUIDELINE STATEMENT 33/34
PUL considered volumes 30-80 with absence of obstructing median lobe as an option for patients that desire preservation of erectile and ejaculatory function
GUIDELINE STATEMENT 35
TUMT (transferring energy to tissue creating heat, special cooling cath)
GUIDELINE STATMENT 36/37
WVTT (Rezum–water vapor thermal therapy) for volumes 30-80 cc as an option for patients that desire preservation of erectile and ejaculatory function
GUIDELINE STATMENT 38
TUNA IS NOT RECOMMENDED
GUIDELINE STATEMENT 39
HoLEP or ThuLEP considered depending on expertise and prostate size (less txf, AC)
GUIDELINE STATEMENT 40
Robotic water jet (RWT) prostates 30-80 cc (TRUS map and transurethral waterjet robotic hand-piece)
